Abstract Activator of G protein signaling 3 (AGS3) binds Ga i subunits in the GDP-bound state, implicating AGS3 as an important regulator of Ga i -linked receptor (e.g., D2 dopamine and l-opioid) signaling. We examined the ability of AGS3 to modulate recombinant adenylyl cyclase (AC) type 1 and 2 signaling in HEK293 cells following both acute and persistent activation of the D 2L dopamine receptor (D 2L DR). AGS3 expression modestly enhanced the potency of acute quinpirole-induced D 2L DR modulation of AC1 or AC2 activity. AGS3 also promoted desensitization of D 2L DRmediated inhibition of AC1, whereas desensitization of D 2L DR-mediated AC2 activation was significantly attenuated. Additionally, AGS3 reduced D 2L DR-mediated sensitization of AC1 and AC2. These data suggest that AGS3 is involved in altering G protein signaling in a complex fashion that is effector-specific and dependent on the duration of receptor activation.
Introduction
G protein-coupled receptors bind ligands that induce conformational changes in the receptor and facilitate the activation of G protein heterotrimers by exchange of GDP for GTP on the G protein a subunit (Gilman 1987) . Upon activation, the G protein heterotrimer undergoes a conformational change that allows Ga and Gbc subunits to regulate effector proteins such as adenylyl cyclases (ACs) (Coleman et al. 1994; Lambright et al. 1994; Taussig et al. 1994) . The G protein signaling cycle ends by hydrolysis of GTP to GDP on the Ga subunit (Coleman et al. 1994; Mixon et al. 1995) . In addition to G protein-coupled receptor modulation, the G protein activation cycle is sensitive to accessory proteins such as regulators of G protein signaling (RGS) or activator of G protein signaling (AGS) proteins (Blumer et al. 2007; Neubig and Siderovski 2002; Sato et al. 2004 ). These proteins influence G protein signaling and effector activation by modulating the rate of GTP hydrolysis and the availability and/or stability of Ga or Gbc subunits (Blumer et al. 2007; Neubig and Siderovski 2002; Sato et al. 2004) .
The activator of G protein signaling 3 (AGS3) is a G protein regulator that has been linked to adaptive behaviors involved with drugs of abuse (Bowers et al. 2008; Bowers et al. 2004; Yao et al. 2005) . AGS3 was identified as a receptor-independent G protein activator and is thought to bind Ga i subunits in the GDP-bound state, thereby preventing re-association of Ga and Gbc subunits (De Vries et al. 2000; Peterson et al. 2000; Takesono et al. 1999 ). The precise molecular actions of AGS3 have yet to be fully described, however, it is hypothesized that AGS3 expression may specifically adjust the landscape of effector activation by modulating Ga and Gbc subunit signaling. Previous studies examining the actions of AGS3 on G protein-coupled receptor signaling in cell-based assays suggest that the effects of AGS3-like molecules are dependent on the duration of receptor activation. For example, an AGS3 consensus peptide was shown to have no effect on the ability of D 2 DRs to modulate G protein-regulated inwardly rectifying potassium (GIRK) channels acutely, but promoted functional desensitization of this response following repeated receptor activation (Webb et al. 2005) . Furthermore, the actions of AGS3 on a 2 adrenergic receptor regulation of cAMP signaling were explored in CHO cells, which predominantly express AC6 (Varga et al. 1998 ). The acute effects on a 2 adrenergic receptor-mediated AC signaling were not altered, but sensitization of AC in response to persistent a 2 receptor activation was attenuated by AGS3 expression (Sato et al. 2004 ). More recent studies in nucleus accumbens/striatal neurons have suggested that opioid receptor-induced expression of AGS3 enhances the activity of AC5 and AC7 in a protein kinase-dependent manner (Fan et al. 2009 ).
The observations described above suggest a complex mode of AGS3 modulation of receptor-mediated AC signaling. The complexity is further exacerbated by the expression and signaling of multiple AC isoforms that display unique patterns of Ga and Gbc regulation (Sunahara et al. 1996; Watts and Neve 2005) . The present study was designed to examine the effects of AGS3 on G proteincoupled receptor modulation of two recombinant ACs, AC1 and AC2. AC1 is a member of the Ca 2? -stimulated group of ACs and can be activated by the Ca 2? ionophore, A23187, and inhibited by both Ga i and Gbc subunits (Choi et al. 1992; Cumbay and Watts 2001; Taussig et al. 1993) . AC2 is a member of a group of ACs that are conditionally activated by Gbc subunits (Federman et al. 1992; Taussig et al. 1993) . AC2 is also robustly activated by protein kinase C (PKC) phosphorylation in response to phorbol ester stimulation (e.g., PMA) (Bernard et al. 2001; Shen et al. 2012; Yoshimura and Cooper 1993) . The distinct regulatory properties of AC1 and AC2 provide important tools to selectively study the effects of AGS3 expression on G protein-coupled receptor signaling.
It is widely accepted that alterations in cAMP signaling pathways and enhanced activation of dopamine systems in the brain play central roles in the molecular adaptations associated with drug addiction (Carlezon et al. 2005; McClung and Nestler 2003; Nestler 2001 (Missale et al. 1998) . We chose to study D 2L DR signaling based on the overlapping tissue distribution of the D 2L DR with AC1 and AC2 in the brain, and its well-characterized roles in AC signaling and drug abuse, where AGS3 has also been implicated (Maldonado et al. 1997; Phillips et al. 1998; Ralph et al. 1999; Visel et al. 2006; Weiner et al. 1991) . HEK293 cells expressing the D 2L DR together with either AC1 or AC2 were used to explore cAMP signaling in the absence or presence of AGS3. Our studies revealed that AGS3 expression had modest, but significant potentiating effects on acute D 2L DR modulation of AC1 or AC2 activity. In contrast, AGS3 displayed differential effects on AC regulation following persistent D 2L DR activation. These findings, along with those reported in the literature, suggest that AGS3 modulates AC signaling in a manner that is isoform-specific and dependent on the duration of receptor activation.
Materials and Methods

Materials
[ 3 H]-cAMP (33 Ci/mmol) was purchased from PerkinElmer Life and Analytical Sciences (Boston, MA). Spiperone, (±)-quinpirole, A23187, 3-isobutyl-1-methylxanthine (IBMX), G418, Dulbecco's modified Eagle's medium (DMEM), and trichloroacetic acid were purchased from Sigma-Aldrich (St. Louis, MO). Phorbol 12-myristate 13-acetate (PMA) was purchased from Tocris Bioscience (Ellisville, MO). Lipofectamine 2000 and Zeocin were purchased from Invitrogen (Carlsbad, CA). FetalClone I (FCI) serum, bovine calf serum (BCS), and Earle's balanced salt solution (EBSS) were purchased from Hyclone (Logan, UT). Hygromycin B was purchased from Calbiochem (La Jolla, CA).
Cell Culture and Stable Cell Line Generation HEK293 cells stably expressing AC1 or AC2 were grown in DMEM supplemented with 5 % FCI, 5 % BCS, 1 unit/ml penicillin, 1 lg/ml streptomycin, 2.5 ng/ml amphotericin B, and either 100 lg/ml Hygromycin B (HEK-AC1) or 300 lg/ml G418 (HEK-AC2) and were maintained in a humidified incubator at 37°C with 5 % CO 2 . Cell lines were transfected with the dual expression vector pBudCE4 with the gene for the human D 2L DR driven by the CMV promoter and either rat AGS3-Venus (long splice variant), AGS3-Q/ A-Venus, or no gene behind the EF-1a promoter. Several studies have utilized AGS3 fused with a fluorescent protein at the c-terminus Oner et al. 2010; Oner et al. 2013; Vural et al. 2010 ) and these studies suggest that the AGS3-fluorescent fusion proteins retain similar cellular localization Blumer et al. 2002; Pizzinat et al. 2001; Vural et al. 2010) and interaction with Ga i subunits (De Vries et al. 2000; Oner et al. 2010; Oner et al. 2013; Peterson et al. 2000 ) as compared to untagged AGS3. Stable transfections were carried out with Lipofectamine 2000 according to the manufacturer's protocol. Clones were isolated by selection with Zeocin (200 lg/ml) and characterized for specific AC function by cAMP accumulation assays (Online Resource 1), D 2L DR expression by radioligand binding (Online Resource 2), and AGS3 expression by fluorescence microscopy (Online Resource 3).
Cyclic AMP Accumulation Assay
Cells were grown to confluency in 48-well plates and cAMP assays were performed on ice in assay buffer (EBSS containing 15 mM Na ? -HEPES, 2 % BCS, and 0.02 % ascorbic acid). For acute cAMP accumulation experiments, cells were stimulated at 37°C for 15 min in the presence of 500 lM IBMX. The stimulation buffer was decanted and cells were lysed with ice-cold 3 % trichloroacetic acid. The plate was stored at 4°C for at least 1 h before cAMP quantification. For persistent receptor activation experiments, cells were grown to confluency in 48-well plates and pretreated in assay buffer with either vehicle or 1 lM (±)-quinpirole for 2 h at 37°C and 5 % CO 2 . Cells were washed with assay buffer thrice (3 min each), and subsequently stimulated as described for acute cAMP accumulation assays. For desensitization assays, pretreatments were carried out as described above, followed by re-activation of the receptor as described for acute cAMP accumulation experiments. For heterologous sensitization experiments, subsequent stimulation was achieved by selective activation of AC isoforms (AC1, 10 lM A23187; AC2, 1 lM PMA) in the presence of 500 lM IBMX and 1 lM spiperone to block residual agonist binding from the pretreatment.
Cyclic AMP Quantification
Cyclic AMP was quantified using a competitive binding assay (Przybyla and Watts 2010) . Duplicate samples of lysate from the cAMP accumulation assay were added to reaction tubes, followed sequentially by [ 3 H]-cAMP (*1 nM final concentration), and cAMP-binding protein (*100 lg of crude bovine adrenal extract) in 500 lL of cAMP-binding buffer (100 mM Tris-HCl, 100 mM NaCl, 3 mM EDTA, pH 7.4). The assay was carried out at 4°C for 2 h and harvested by filtration through Millipore FB 96-well filter plates, and radioactivity was quantified on a TopCount NXT scintillation counter (Perkin Elmer). Cyclic AMP concentrations were estimated from a standard curve ranging from 300 pmol to 3 nmol cAMP.
Data Analysis
GraphPad Prism software was used to generate all doseresponse curves (GraphPad Software, San Diego, CA). All logIC 50 /logEC 50 , and maximal activation/inhibition values were calculated in GraphPad Prism using a non-linear regression and sigmoidal dose-response equation and were analyzed by unpaired t tests.
Results and Discussion
AGS3 interacts with the GDP-bound state of Ga i subunits, and it has been suggested that this interaction prevents the re-association of Ga i and Gbc subunits (De Vries et al. 2000; Peterson et al. 2000) . The interaction between AGS3 and Ga i -GDP may cause altered G protein signaling through effectors regulated by Ga i and Gbc subunits. AC isoforms display differential patterns of regulation by G protein subunits (Sunahara et al. 1996; Watts and Neve 2005) . Given that AGS3 may alter signaling by Ga i and/or Gbc subunits, and AC isoforms are differentially regulated by G protein subunits, we were interested in studying the effects of AGS3 expression on the regulation of AC isoforms following acute and persistent activation of D 2L DRs.
Modulation of Acute D 2L DR-Mediated AC1 and AC2 Signaling by AGS3 Expression Our initial studies used HEK293 cells stably expressing AC1 or AC2 and the D 2L DR. Recombinant AC1 can be selectively activated in HEK293 cells by Ca 2? using the calcium ionophore, A23187 or by capacitative calcium entry (Choi et al. 1992; Cooper et al. 1994 ). To observe acute Ga i regulation, AC1 activity was selectively increased using A23187, and inhibition by the D 2 DR agonist quinpirole was examined. A23187-stimulated AC1 activity was inhibited by 54 ± 2 % with a logIC 50 of -8.08 ± 0.13 (Fig. 1a) . In cells expressing AGS3, modest, but significant increases in maximal inhibition (67 ± 4 %) and potency (logIC 50 = -8.83 ± 0.19) for D 2L DR-mediated inhibition of AC1 activity by quinpirole were observed. AC2 is conditionally stimulated (requiring co-activation of AC2 by Ga s or PKC) by Gbc subunits following the activation of Ga i/o -coupled receptors (Tsu and Wong 1996; Yoshimura and Cooper 1993; Zimmermann and Taussig 1996) . To study acute Gbc subunit signaling, HEK293 cells stably expressing AC2 and the D 2L DR were incubated with PMA to stimulate AC2, and quinpirole to activate the D 2L DR (subsequently releasing Gbc subunits). Maximal activation of the D 2L DR by quinpirole resulted in a robust increase in cAMP accumulation through conditional activation of AC2 (240 ± 18 % of PMA response) with a logEC 50 of -7.05 ± 0.06 (Fig. 1b) . AGS3 co-expression did not affect the maximal activation of AC2 (250 ± 20 % of PMA response), but a significant shift in the potency (log EC 50 = -7.45 ± 0.06) of quinpirole-potentiated cAMP accumulation was observed as compared to cells not expressing AGS3. Though modest, the effects of AGS3 on D 2L DR-mediated regulation of AC1 or AC2 are consistent with enhanced Gbc subunit modulation of each effector. Specifically, Gbc subunits inhibit signaling mediated by AC1, but increase AC2 activity, and AGS3 expression augments the potency of these effects, presumably by binding Cell Mol Neurobiol (2013) 33:551-558 553 Ga i subunits. The effects of AGS3 expression on acute D 2L DR-mediated AC1 or AC2 activity are contrary to other cell-based studies examining the effects of AGS3 expression on acute G protein signaling. For example, AGS3 did not alter a 2 -adrenergic receptor-inhibited AC activity in CHO cells (Sato et al. 2004) . Perhaps more relevant to our D 2 DR-AC studies is the observation that AGS3 failed to alter D 2S DR-stimulated GIRK channel activity, a Gbc-mediated signaling event (Webb et al. 2005 ). These findings suggest that AGS3 may display AC-specific or even effector-specific regulation of acute G protein signaling.
Desensitization of D 2L DR-Mediated AC1 and AC2 Signaling
In addition to studying AC regulation by acute activation of the D 2L DR, we were also interested in studying desensitization of the D 2L DR. Cells stably expressing AC1 and the D 2L DR were treated with quinpirole for 2 h in an effort to promote functional receptor desensitization. Following washing, cells were re-exposed to quinpirole and the subsequent cAMP accumulation was measured. Persistent D 2L DR activation by quinpirole failed to induce significant desensitization of D 2L DR modulation of AC1 activity. Specifically, quinpirole treatment maximally inhibited A23187-stimulated AC1 activity by 56 ± 9.1 % with a log IC 50 of -8.0 ± 0.20 following persistent D 2L DR activation, as compared to maximum inhibition of 59 ± 1.8 % and log IC 50 of -8.5 ± 0.20 after vehicle pretreatment (n = 2). We then examined the effects of AGS3 expression on D 2L DR-modulated AC1 activity following persistent D 2L DR stimulation. These experiments revealed that AGS3-expressing cells pretreated with quinpirole displayed a desensitization of D 2L DR-modulated AC1 inhibition that was manifested as a significant loss of maximal inhibition (60 ± 6 %) compared to vehicle pretreated cells (84 ± 8 %), but without a significant change in potency (logIC 50 = -8.03 ± 0.39 and -8.64 ± 0.17, respectively) (Fig. 2) . The AGS3-promoted desensitization of AC1 inhibition may occur through interactions with Ga i subunits that are involved in the inhibition AC1 activity. However, it has been suggested that Ga i -AGS3 complexes can couple with, and be regulated by Ga i -coupled receptors upon agonist activation, allowing for the possibility of indirect modulation of downstream Gbc subunit signaling . Furthermore, an AGS3 consensus peptide disrupted Gbc subunit activation of GIRK channels following repeated stimulation of D 2S DRs (Webb et al. 2005) . Given that Gbc subunits inhibit AC1 activity (Taussig et al. 1993) , these data present the possibility that the desensitization of AC1 inhibition is also associated with altered Gbc subunit signaling. In contrast to AC1, a complete desensitization of D 2L DR-mediated potentiation of AC2 activation was observed following quinpirole pretreatment in D 2L DR-AC2 cells. Specifically, quinpirole pretreatment resulted in 103 ± 11 % desensitization of D 2L DR-mediated potentiation of AC2 activity as compared to vehicle pretreatment (Fig. 3) . These observations suggest potential differences in the general mechanisms for desensitization of D 2L DRmodulated AC1 and AC2 activity. Such mechanisms presumably reflect the differential regulatory properties of AC1 and AC2 that involve G protein modulation (Hanoune and Defer 2001) . Subsequent experiments examined the effects of AGS3 on desensitization of D 2L DR-potentiated AC2 activity. Surprisingly, expression of AGS3 resulted in significantly less desensitization (46 ± 7 %) of D 2L DRmediated potentiation of AC2 activity (Fig. 3) . The specificity of this blockade was probed by expressing an AGS3 mutant that does not bind Ga i subunits, AGS3-Q/A (Peterson et al. 2002) . AGS3-Q/A failed to significantly alter quinpirole-induced desensitization of D 2L DR-AC2 signaling (78 ± 3 %), suggesting that AGS3 expression inhibits desensitization of D 2L DR signaling through AC2 in a manner that is dependent on the interaction of AGS3 with Ga i .
Effects of AGS3 Expression on Heterologous Sensitization of AC1 and AC2
In addition to desensitization, persistent activation of many Ga i/o -coupled receptors (e.g., D 2 dopamine and l-opioid) results in enhanced subsequent AC activation.
This heterologous sensitization (a.k.a. superactivation) of cAMP signaling involves both Ga i/o and Gbc subunits (Watts and Neve 2005) , but the mechanisms of sensitization for AC1 and AC2 appear to differ (Cumbay and Watts 2001) . The functional effects of AGS3 expression on AC sensitization following persistent activation of the D 2L DR were examined. For these experiments, cells expressing AC1 and the D 2L DR were stimulated with the D 2 DR agonist quinpirole for 2 h, followed by selective activation of AC1 by A23187. Quinpirole pretreatment resulted in a 235 ± 4 % enhancement of A23187-stimulated AC1 activity compared to the vehicle pretreatment (Fig. 4a) . Cells co-expressing AGS3 displayed a reduction in subsequent AC1 stimulation (178 ± 12 % of vehicle condition) following quinpirole pretreatment, suggesting that AGS3 expression attenuates AC1 sensitization by *40 %. The effects of AGS3 expression on the regulation of AC2 following persistent D 2L DR activation were also explored. AC2 displayed an enhanced responsiveness (182 ± 9 % of vehicle condition) to stimulation by PMA following quinpirole pretreatment (Fig. 4b) . The D 2L DR-mediated sensitization of AC2 was nearly eliminated (120 ± 3 % of vehicle condition) in AGS3 expressing cells. In contrast, AGS3-Q/A did not alter D 2L DR-mediated sensitization of AC2 (202 ± 10 % of vehicle response), suggesting that AGS3-Ga i subunit interactions are involved in the inhibition of AC2 sensitization. The ability of AGS3 expression to prevent heterologous sensitization of AC1 and AC2 is similar to that observed by expressing the Gbc subunit scavenger, bARK-CT [ (Koch et al. 1994; Nguyen and Watts 2005) and data not shown for AC2]. These data add support to the hypothesis that AGS3 potentially alters Gbc subunit signaling following persistent G i -coupled receptor activation Webb et al. 2005) .
The inhibition of D 2L DR-mediated sensitization of AC1 and AC2 by AGS3 expression is consistent with a report revealing that AGS3 inhibits a 2 -adrenergic receptor-mediated sensitization of AC isoforms expressed in CHO cells (predominantly expressing AC6) (Sato et al. 2004; Varga et al. 1998) . In contrast, evidence suggests that opioid receptor-induced up-regulation of AGS3 expression mediates sensitization of AC5 and AC7 in nucleus accumbens/ striatal neurons (Fan et al. 2009 ). These differential effects suggest an isoform-dependence for sensitization that may reflect complex and unique isoform-specific mechanisms of AC sensitization involving Ga i , Gbc, or a combination of the two, and subsequently altered downstream signaling. Alternatively, the isoform-specific effects on AC signaling may reflect differences in receptor types, cell types, or experimental paradigms. The differential effects of AGS3 on AC sensitization, desensitization, and acute D 2L DRmediated signaling are similar to what has been observed for ligands that possess functional selectivity (or promote agonist-directed trafficking) (Kenakin 1995) . Such an observation posits that receptor-and effector-modulating signaling molecules introduce an additional level of complexity for cell signaling studies. For example, AGS3 differentially alters desensitization of D 2L DR-mediated modulation of AC1 and AC2, while reducing sensitization of both AC isoforms. These complex mechanisms for regulation by AGS3 in vitro suggest the opportunity for greater signaling diversity in vivo.
Significance of AGS3-Regulated AC Signaling to Drugs of Abuse
In vivo studies suggest that AGS3 has a ''gatekeeper'' role for drug-seeking behavior in response to heroin, cocaine, or ethanol. For example, knocking out AGS3 expression in specific brain regions resulted in a loss of drug-seeking behavior or cocaine-induced locomotor sensitization (Bowers et al. 2008; Bowers et al. 2004; Yao et al. 2005) . Interestingly, AGS3 expression is up-regulated in the nucleus accumbens core or prefrontal cortex during withdrawal periods following prolonged ethanol or cocaine self-administration, respectively (Bowers et al. 2008; Bowers et al. 2004 ). In conjunction with overwhelming evidence that dopamine systems and cAMP signaling pathways are involved in drug addiction (Carlezon et al. 2005; McClung and Nestler 2003; Nestler 2001) , our data suggest that AGS3 overexpression during periods of withdrawal may change the profile of signaling through specific AC isoforms in response to persistent Ga i/o -coupled receptor activation. In addition, recent studies with AC knockout mice suggest a role for Ca 2? -stimulated ACs (AC1 and AC8) in the regulation of cocaine behavioral sensitization (DiRocco et al. 2009 ). It will be important to study the role of individual AC isoforms in specific brain regions in the context of drug-seeking behavior, where AGS3 may be exerting its effects by fine-tuning D 2L DRmediated signaling through distinct AC isoforms.
Conclusions
Taken as a whole, our data suggest that AGS3 expression alters D 2L DR-mediated regulation of effector proteins in a manner that is effector-specific and dependent on the duration of Ga i -coupled receptor activation. The expression of AGS3 has modest, but potency-enhancing effects on effector modulation in response to acute Ga i -coupled receptor stimulation. Expression of AGS3 promoted desensitization of prolonged D 2L DR-mediated signaling through AC1, but reduced desensitization of AC2 signaling. In addition, D 2L DR-mediated sensitization of AC1 and AC2 signaling was attenuated by AGS3 expression. It is becoming apparent that AGS3 is involved in altering G protein signaling in a complex fashion that is effector-specific. 
